8.2. f. A return of mixed blastic/lytic lesions significantly 
(> 50%) to normal bone architecture agreed by two 
independent investigators will constitute a PR. 
8 . 3 Stable Disease: 
No significant change in measurable or evaluable disease for at 
least 4 weeks (> 8 weeks for bone metastases). 
No increase in size of any known malignant disease. 
No appearance of any known malignant disease. 
This designation includes decrease in malignant disease of < 50% 
or increase in malignant disease of < 25%. 
8 . 4 Progression : 
Significant increase in size or number of malignant lesions. 
Measurable, bidimensional or unidimensional: 
a. 25% or greater increase over original measurements in 
the sum of the product of the two largest perpendicular 
diameters of measurable lesions. 
b. 50% or greater increase in size of product of diameters 
if only one lesion is available for measurement and was 
> 2 cm at the initiation of therapy. 
c. 30% or greater increase in linear (unidimensional) tumor 
measurements for > 4 weeks. 
d. Appearance of any new malignant lesions. 
[332] 
Recombinant DNA Research, Volume 17 
